X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs IPCA LABS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA IPCA LABS GLENMARK PHARMA/
IPCA LABS
 
P/E (TTM) x 24.3 28.4 85.7% View Chart
P/BV x 3.8 3.4 113.2% View Chart
Dividend Yield % 0.3 0.1 227.3%  

Financials

 GLENMARK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
IPCA LABS
Mar-18
GLENMARK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs993695 142.8%   
Low Rs729400 182.3%   
Sales per share (Unadj.) Rs325.5260.2 125.1%  
Earnings per share (Unadj.) Rs39.319.0 207.1%  
Cash flow per share (Unadj.) Rs48.733.1 147.2%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.2 127.2%  
Book value per share (Unadj.) Rs159.2213.0 74.7%  
Shares outstanding (eoy) m282.17126.20 223.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.1 125.7%   
Avg P/E ratio x21.928.9 75.9%  
P/CF ratio (eoy) x17.716.6 106.8%  
Price / Book Value ratio x5.42.6 210.4%  
Dividend payout %5.15.3 96.6%   
Avg Mkt Cap Rs m242,99169,120 351.6%   
No. of employees `00013.013.3 97.8%   
Total wages/salary Rs m16,4087,359 223.0%   
Avg. sales/employee Rs Th7,083.92,477.4 285.9%   
Avg. wages/employee Rs Th1,265.4555.2 227.9%   
Avg. net profit/employee Rs Th855.1180.6 473.3%   
INCOME DATA
Net Sales Rs m91,85732,836 279.7%  
Other income Rs m374418 89.4%   
Total revenues Rs m92,23033,254 277.4%   
Gross profit Rs m20,3674,505 452.1%  
Depreciation Rs m2,6441,777 148.7%   
Interest Rs m2,373240 988.0%   
Profit before tax Rs m15,7242,905 541.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827511 748.7%   
Profit after tax Rs m11,0882,394 463.1%  
Gross profit margin %22.213.7 161.6%  
Effective tax rate %24.317.6 138.3%   
Net profit margin %12.17.3 165.5%  
BALANCE SHEET DATA
Current assets Rs m68,74619,455 353.4%   
Current liabilities Rs m27,02710,076 268.2%   
Net working cap to sales %45.428.6 159.0%  
Current ratio x2.51.9 131.7%  
Inventory Days Days8598 86.8%  
Debtors Days Days9667 142.7%  
Net fixed assets Rs m24,13220,260 119.1%   
Share capital Rs m282252 111.8%   
"Free" reserves Rs m44,64326,633 167.6%   
Net worth Rs m44,92526,886 167.1%   
Long term debt Rs m45,3632,340 1,938.5%   
Total assets Rs m117,63941,173 285.7%  
Interest coverage x7.613.1 58.2%   
Debt to equity ratio x1.00.1 1,160.1%  
Sales to assets ratio x0.80.8 97.9%   
Return on assets %11.46.4 178.8%  
Return on equity %24.78.9 277.1%  
Return on capital %19.110.8 177.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m56,15215,642 359.0%   
Fx outflow Rs m8,0844,884 165.5%   
Net fx Rs m48,06810,759 446.8%   
CASH FLOW
From Operations Rs m6,5743,411 192.7%  
From Investments Rs m-7,124-1,354 526.1%  
From Financial Activity Rs m5,432-1,304 -416.5%  
Net Cashflow Rs m1,992753 264.5%  

Share Holding

Indian Promoters % 48.3 45.9 105.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.4 60.5%  
FIIs % 34.4 25.3 136.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.4 60.3%  
Shareholders   56,727 36,892 153.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS